Nanomedicines in Cancer Therapy

  • Enas Abu-Qudais
  • Balakumar ChandrasekaranEmail author
  • Sara Samarneh
  • Ghadir Kassab
Part of the Engineering Materials book series (ENG.MAT.)


Cancer is one of the most controversial diseases known for humanity and emerged as a global health problem all the time. The drug discovery scientists and clinicians have attempted to cure cancer since centuries. Conventional cancer treatments such as radiotherapy and chemotherapy have many limitations including low specificity, lack of stability, rapid drug clearance, biodegradation and limited targeting besides number of side effects associated with these treatments on the actual patients. Nanomedicine has evolved over the past few years and became a breakthrough technology for the diagnosis and the treatment of several cancer types. Specifically, the drug is being carried out through carriers called nanoparticles in which the properties of these carriers are very important for the successful treatment of deadly diseases like cancer. In this chapter, we describe the application of nanotechnology and nanomedicines in the diagnosis and treatment of cancer. Further, we discuss the targeted-nanodrug delivery to cancer cells in a broad context. Moreover, we provide a glimpse on marketed nanomedicines available for the management of cancer.


Nanodrug delivery Nanomedicine Brain cancer Breast cancer Lung cancer Nanoparticles 

List of Abbreviations


ATP-binding cassette


Gold nanoparticles


Blood brain barrier


B-cell lymphoma protein extra-large




Brain tumor–cell barrier


Brain tumor stem cells


Convection-enhanced delivery


Enhanced permeability and retention effect


Food and drug administration




Human epidermal receptor 2


Herpes simplex virus






Lutenizing hormone


Monoclonal antibodies


Multi drug resistance


Matrix metalloproteinase


Mismatch repair


Macrophage phagocytic system


Multiple myeloma




Poly(β-amino esters)


Photo dynamic therapy


Poly ethylene glycol


Prostate specific membrane




Poly-(lactic acid-coglycolic acid)


Prostate-specific antigen


Photothermal therapy




Tumor-associated macrophages


Tumor microenvironment


Triple-negative breast cancer


TNF-related apoptosis inducing ligand


World health organization



Authors wish to thank Dr. Yazan Al-Bataineh (The Dean), Prof. Abdul Muttaleb Jaber, Prof. Mutaz Sheikh Salem (The President) and Prof. Marwan Kamal (University Counsellor) of Philadelphia University, Jordan for the constant support, motivation and research funding to BC (467/34/100 PU).


  1. Abdulkareem, I., & Zurmi, I. (2012). Review of hormonal treatment of breast cancer. Nigerian Journal of Clinical Practice, 15, 9–14. Scholar
  2. Agarwal, S., Sane, R., Oberoi, R., et al. (2011). Delivery of molecularly targeted therapy to malignant glioma, a disease of the whole brain. Expert Reviews in Molecular Medicine, 13, 1–27. Scholar
  3. Agemy, L., Friedmann-Morvinski, D., Kotamraju, V. R., et al. (2011). Targeted nanoparticle enhanced proapoptotic peptide as potential therapy for glioblastoma. Proceedings of National Academy of Sciences, 108, 17450–17455. Scholar
  4. Akilo, O. D., Choonara, Y. E., Strydom, A. M., et al. (2016). AN in vitro evaluation of a carmustine-loaded Nano-co-Plex for potential magnetic-targeted intranasal delivery to the brain. International Journal of Pharmaceutics, 500, 196–209. Scholar
  5. Amer, M. H. (2014). Gene therapy for cancer: present status and future perspective. Molecular and Cellular Therapies, 2, 1–19. Scholar
  6. Anselmo, A. C., & Mitragotri, S. (2016). Nanoparticles in the clinic. Bioengineering Translational Medicine, 1, 10–29. Scholar
  7. Arnida, M. A., & Ghandehari, H. (2010). Cellular uptake and toxicity of gold nanoparticles in prostate cancer cells: A comparative study of rods and spheres. Journal of Applied Toxicology, 30, 212–217. Scholar
  8. Arranja, A. G., Pathak, V., Lammers, T., & Shi, Y. (2017). Tumor-targeted nanomedicines for cancer theranostics. Pharmacological Research, 115, 87–95. Scholar
  9. Arruebo, M., Vilaboa, N., Sáez-Gutierrez, B., et al. (2011). Assessment of the evolution of cancer treatment therapies. Cancers (Basel)., 3, 3279–3330. Scholar
  10. Blagosklonny, M. V. (2003). Targeting cancer cells by exploiting their resistance. Trends in Molecular Medicine, 9, 307–312. Scholar
  11. Bobo, D., Robinson, K. J., Islam, J., et al. (2016). Nanoparticle-based medicines: A review of FDA-approved materials and clinical trials to date. Pharmaceutical Research, 33, 2373–2387. Scholar
  12. Bourzac, K. (2016). News feature: Cancer nanomedicine, reengineered. Proceedings of National Academy of Sciences, 113, 12600–12603. Scholar
  13. Brown, J. S., Sundar, R., & Lopez, J. (2018). Combining DNA damaging therapeutics with immunotherapy: More haste, less speed. British Journal of Cancer, 118, 312–324. Scholar
  14. Cai, W., Gao, T., Hong, H., & Sun, J. (2008). Applications of gold nanoparticles in cancer nanotechnology. Nanotechnology, Science and Applications, 1, 17–32. Scholar
  15. Chames, P., Van Regenmortel, M., Weiss, E., & Baty, D. (2009). Therapeutic antibodies: Successes, limitations and hopes for the future. British Journal of Pharmacology, 157, 220–233. Scholar
  16. Chang, T. C., Shiah, H. S., Yang, C. H., et al. (2015). Phase I study of nanoliposomal irinotecan (PEP02) in advanced solid tumor patients. Cancer Chemotherapy and Pharmacology, 75, 579–586. Scholar
  17. Cullis, J., Siolas, D., Avanzi, A., et al. (2017). Macropinocytosis of nab-paclitaxel drives macrophage activation in pancreatic cancer. Cancer Immunology Research, 5, 182–190. Scholar
  18. Danhier, F., Feron, O., & Préat, V. (2010). To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anti-cancer drug delivery. Journal of Controlled Release, 148, 135–146. Scholar
  19. Das, S. K., Menezes, M. E., Bhatia, S., et al. (2015). Gene therapies for cancer: Strategies, challenges and successes. Journal of Cellular Physiology, 230, 259–271. Scholar
  20. David, A. (2017). Peptide ligand-modified nanomedicines for targeting cells at the tumor microenvironment. Advanced Drug Delivery Reviews, 119, 120–142. Scholar
  21. Elizondo, E., Moreno, E., Cabrera, I., et al. (2011). Liposomes and other vesicular systems: Structural characteristics, methods of preparation, and use in nanomedicine. Progress in Molecular Biology and Translational Science, 104, 1–52. Scholar
  22. Elzoghby, A. O., Samy, W. M., & Elgindy, N. A. (2012). Albumin-based nanoparticles as potential controlled release drug delivery systems. Journal of Controlled Release, 157, 168–182. Scholar
  23. Ernsting, M. J., Murakami, M., Undzys, E., et al. (2012). A docetaxel-carboxymethylcellulose nanoparticle outperforms the approved taxane nanoformulation, Abraxane, in mouse tumor models with significant control of metastases. Journal of Controlled Release, 162, 575–581. Scholar
  24. Falzone, L., Salomone, S., & Libra, M. (2018). Evolution of cancer pharmacological treatments at the turn of the third millennium. Frontiers in Pharmacology, 9, 1–26. Scholar
  25. Farokhzad, O. C., Cheng, J., Teply, B. A., et al. (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proceedings of National Academy of Sciences, 103, 6315–6320. Scholar
  26. Firdhouse, M. J., & Lalitha, P. (2013). Biosynthesis of silver nanoparticles using the extract of Alternanthera sessilis-antiproliferative effect against prostate cancer cells. Cancer Nanotechnology, 4, 137–143. Scholar
  27. Frenkel, V. (2008). Ultrasound mediated delivery of drugs and genes to solid tumors. Advanced Drug Delivery Reviews, 60, 1193–1208. Scholar
  28. Gardikis, K., Hatziantoniou, S., Signorelli, M., et al. (2010). Thermodynamic and structural characterization of Liposomal-Locked in-Dendrimers as drug carriers. Colloids Surfaces B Biointerfaces, 81, 11–19. Scholar
  29. Gelperina, S., Kisich, K., Iseman, M. D., & Heifets, L. (2005). The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. American Journal of Respiratory and Critical Care Medicine, 172, 1487–1490. Scholar
  30. Gianni, L., Pienkowski, T., Im, Y.-H., et al. (2016). 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): A multicentre, open-label, phase 2 randomised trial. The lancet Oncology, 17, 791–800. Scholar
  31. Gulati, K., Aw, M. S., & Losic, D. (2012). Nanoengineered drug-releasing Ti wires as an alternative for local delivery of chemotherapeutics in the brain. International Journal of Nanomedicine, 7, 2069–2076. Scholar
  32. Gustafson, H. H., Holt-Casper, D., Grainger, D. W., & Ghandehari, H. (2015). Nanoparticle uptake: The phagocyte problem. Nano Today, 10, 487–510. Scholar
  33. Hassanpour, S. H., & Dehghani, M. (2017). Review of cancer from perspective of molecular. Journal of Cancer Research and Practice, 4, 127–129. Scholar
  34. Housman, G., Byler, S., Heerboth, S., et al. (2014). Drug resistance in cancer: An overview. Cancers (Basel), 6, 1769–1792. Scholar
  35. Jaganathan, H., & Godin, B. (2012). Biocompatibility assessment of Si-based nano- and micro-particles. Advanced Drug Delivery Reviews, 64, 1800–1819. Scholar
  36. Jantscheff, P., Esser, N., Graeser, R., et al. (2009). Liposomal gemcitabine (GemLip)—efficient drug against hormone-refractory Du145 and PC-3 prostate cancer xenografts. Prostate, 69, 1151–1163. Scholar
  37. Jiang, X., Xin, H., Ren, Q., et al. (2014). Nanoparticles of 2-deoxy-d-glucose functionalized poly(ethylene glycol)-co-poly(trimethylene carbonate) for dual-targeted drug delivery in glioma treatment. Biomaterials, 35, 518–529. Scholar
  38. Kolishetti, N., Dhar, S., Valencia, P. M., et al. (2010). Engineering of self-assembled nanoparticle platform for precisely controlled combination drug therapy. Proceedings of National Academy of Sciences, 107, 17939–17944. Scholar
  39. Kroon, J., Metselaar, J. M., Storm, G., & van der Pluijm, G. (2014). Liposomal nanomedicines in the treatment of prostate cancer. Cancer Treatment Reviews, 40, 578–584. Scholar
  40. Kumar, S. R. P., Markusic, D. M., Biswas, M., et al. (2016). Clinical development of gene therapy: Results and lessons from recent successes. Therapy-Methods & Clinical Development, 3, 1–11. Scholar
  41. Leece, R., Xu, J., Ostrom, Q. T., et al. (2017). Global incidence of malignant brain and other central nervous system tumors by histology, 2003–2007. Neuro Oncology, 19, 1553–1564. Scholar
  42. Li, H.-F., Wu, C., Xia, M., et al. (2015). Targeted and controlled drug delivery using a temperature and ultra-violet responsive liposome with excellent breast cancer suppressing ability. RSC Advances, 5, 27630–27639. Scholar
  43. Li, H., Jin, H., Wan, W., et al. (2018). Cancer nanomedicine: mechanisms, obstacles and strategies. Nanomedicine, 23, 1639–1656. Scholar
  44. Lin, S. H., & Kleinberg, L. R. (2008). Carmustine wafers: Localized delivery of chemotherapeutic agents in CNS malignancies. Expert Review of Anticancer Therapy, 8, 343–359. Scholar
  45. Liu, L., Ghaemi, A., Gekle, S., & Agarwal, S. (2016). One-component dual actuation: Poly(NIPAM) can actuate to stable 3D forms with reversible size change. Advanced Materials, 28, 9792–9796. Scholar
  46. Liu, P., Wang, Z., Brown, S., et al. (2014). Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo. Oncotarget, 5, 7471–7485. Scholar
  47. Luqmani, Y. A. (2005). Mechanisms of drug resistance in cancer chemotherapy. Medical Principles and Practice, 14, 35–48. Scholar
  48. Mahmoudi, M., Lynch, I., Ejtehadi, M. R., et al. (2011). Protein − nanoparticle interactions: Opportunities and challenges. Chemical Reviews, 111, 5610–5637. Scholar
  49. Marquette, C., & Nabell, L. (2012). Chemotherapy-resistant metastatic breast cancer. Current Treatment Options in Oncology, 13, 263–275. Scholar
  50. Meyers, J. D., Doane, T., Burda, C., & Basilion, J. P. (2013). Nanoparticles for imaging and treating brain cancer. Nanomedicine (Lond), 8, 123–143. Scholar
  51. Mody, V. V., Siwale, R., Singh, A., & Mody, H. R. (2010). Introduction to metallic nanoparticles. Journal of Pharmacy and Bioallied Sciences, 2, 282–289. Scholar
  52. Montanari, M., Fabbri, F., Rondini, E., et al. (2012). Phase II trial of non-pegylated liposomal doxorubicin and low-dose prednisone in second-line chemotherapy for hormone-refractory prostate cancer. Tumori Journal, 98, 696–701. Scholar
  53. Mross K, Kratz F (2011) Limits of conventional cancer chemotherapy. In Drug delivery in oncology: From basic research to cancer therapy (vol. 1, pp. 1–31).
  54. Muntimadugu, E., Kumar, R., Saladi, S., et al. (2016). CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel. Colloids Surfaces B Biointerfaces, 143, 532–546. Scholar
  55. Mylonakis, N., Athanasiou, A., Ziras, N., et al. (2010). Phase II study of liposomal cisplatin (LipoplatinTM) plus gemcitabine versus cisplatin plus gemcitabine as first line treatment in inoperable (stage IIIB/IV) non-small cell lung cancer. Lung Cancer, 68, 240–247. Scholar
  56. Nabipour, I., & Assadi, M. (2015). Converging technologies: Shaping the future of medicine. Iranian South Medical Journal, 17, 1045–1067.
  57. Nance, E., Zhang, C., Shih, T.-Y., et al. (2014). Brain-penetrating nanoparticles improve paclitaxel efficacy in malignant glioma following local administration. ACS Nano, 8, 10655–10664. Scholar
  58. Noy, R., & Pollard, J. W. (2014). Tumor-Associated macrophages: From mechanisms to therapy. Immunity, 41, 49–61. Scholar
  59. Oiseth, S. J., & Aziz, M. S. (2017). Cancer immunotherapy: A brief review of the history, possibilities, and challenges ahead. Journal Cancer Metastasis and Treatment, 3, 250–261. Scholar
  60. Otsuka, H., Nagasaki, Y., & Kataoka, K. (2012). PEGylated nanoparticles for biological and pharmaceutical applications. Advanced Drug Delivery Reviews, 64, 246–255. Scholar
  61. Owens, D. E., & Peppas, N. A. (2006). Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. International Journal of Pharmaceutics, 307, 93–102. Scholar
  62. Pal, S. L., Jana, U., Manna, P. K., et al. (2011). Nanoparticle: An overview of preparation and characterization. Journal of Applied Pharmaceutical Science, 1, 228–234.Google Scholar
  63. Peer, D., Karp, J. M., Hong, S., et al. (2007). Nanocarriers as an emerging platform for cancer therapy. Nature Nanotechnology, 2, 751–760. Scholar
  64. Perrault, S. D., Walkey, C., Jennings, T., et al. (2009). Mediating tumor targeting efficiency of nanoparticles through design. Nano Letters, 9, 1909–1915. Scholar
  65. Pham, E., Yin, M., Peters, C. G., et al. (2016). Preclinical efficacy of bevacizumab with CRLX101, an investigational nanoparticle–drug conjugate, in treatment of metastatic triple-negative breast cancer. Cancer Research, 76, 4493–4503. Scholar
  66. Qian, L., Zheng, J., Wang, K., et al. (2013). Cationic core–shell nanoparticles with carmustine contained within O6-benzylguanine shell for glioma therapy. Biomaterials, 34, 8968–8978. Scholar
  67. Ranganath, S. H., Fu, Y., Arifin, D. Y., et al. (2010). The use of submicron/nanoscale PLGA implants to deliver paclitaxel with enhanced pharmacokinetics and therapeutic efficacy in intracranial glioblastoma in mice. Biomaterials, 31, 5199–5207. Scholar
  68. Reddy, G. R., Bhojani, M. S., McConville, P., et al. (2006). Vascular targeted nanoparticles for imaging and treatment of brain tumors. Clinical Cancer Research, 12, 6677–6686. Scholar
  69. Sandanaraj, B. S., Gremlich, H.-U., Kneuer, R., et al. (2010). Fluorescent nanoprobes as a biomarker for increased vascular permeability: Implications in diagnosis and treatment of cancer and inflammation. Bioconjugate Chemistry, 21, 93–101. Scholar
  70. Sengupta, S., & Kulkarni, A. (2013). Design principles for clinical efficacy of cancer nanomedicine: A look into the basics. ACS Nano, 7, 2878–2882. Scholar
  71. Shi, J., Kantoff, P. W., Wooster, R., & Farokhzad, O. C. (2017). Cancer nanomedicine: Progress, challenges and opportunities. Nature Reviews Cancer, 17, 20–37. Scholar
  72. Siegel, R. L., Miller, K. D., & Jemal, A. (2018). Cancer statistics, 2018. CA: A Cancer Journal for Clinicians, 68, 7–30. Scholar
  73. Singh, P. K., Doley, J., Kumar, G. R., et al. (2012). Oncolytic viruses & their specific targeting to tumour cells. Indian Journal of Medical Research, 136, 571–584.Google Scholar
  74. Sosnik, A., & Carcaboso, A. M. (2014). Nanomedicines in the future of pediatric therapy. Advanced Drug Delivery Reviews, 73, 140–161. Scholar
  75. Stephen, Z. R., Kievit, F. M., Veiseh, O., et al. (2014). Redox-responsive magnetic nanoparticle for targeted convection-enhanced delivery of O6-benzylguanine to brain tumors. ACS Nano, 8, 10383–10395. Scholar
  76. Sun, T., Zhang, Y. S., Pang, B., et al. (2014). Engineered nanoparticles for drug delivery in cancer therapy. Angewandte Chemie International Edition, 53, 12320–12364. Scholar
  77. Surendiran, A., Sandhiya, S., Pradhan, S. C., & Adithan, C. (2009). Novel applications of nanotechnology in medicine. Indian Journal of Medical Research, 130, 689–701.Google Scholar
  78. Swaminathan, S. K., Roger, E., Toti, U., et al. (2013). CD133-targeted paclitaxel delivery inhibits local tumor recurrence in a mouse model of breast cancer. Journal of Controlled Release, 171, 280–287. Scholar
  79. Sykes, E. A., Chen, J., Zheng, G., & Chan, W. C. W. (2014). Investigating the impact of nanoparticle size on active and passive tumor targeting efficiency. ACS Nano, 8, 5696–5706. Scholar
  80. Thangapazham, R. L., Puri, A., Tele, S., et al. (2008). Evaluation of a nanotechnology-based carrier for delivery of curcumin in prostate cancer cells. International Journal of Oncology, 32, 1119–1123. Scholar
  81. Tiwary, S., Morales, J. E., Kwiatkowski, S. C., et al. (2018). Metastatic brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a. Scientific Reports, 8, 1–13. Scholar
  82. Torre, L. A., Islami, F., Siegel, R. L., et al. (2017). Global cancer in women: Burden and trends. Cancer Epidemiology, Biomarkers and Prevention, 26, 444–457. Scholar
  83. Tzeng, S. Y., & Green, J. J. (2013). Therapeutic nanomedicine for brain cancer. Therapeutic Delivery, 4, 687–704. Scholar
  84. Tzeng, S. Y., Guerrero-Cázares, H., Martinez, E. E., et al. (2011). Non-viral gene delivery nanoparticles based on Poly(β-amino esters) for treatment of glioblastoma. Biomaterials, 32, 5402–5410. Scholar
  85. van der Meel, R., Vehmeijer, L. J. C., Kok, R. J., et al. (2013). Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. Advanced Drug Delivery Reviews, 65, 1284–1298. Scholar
  86. van Sluis, R., Bhujwalla, Z. M., Raghunand, N., et al. (1999). In vivo imaging of extracellular pH using 1H MRSI. Magnetic Resonance in Medicine, 41, 743–750.;2-Z.CrossRefGoogle Scholar
  87. Velaei, K., Samadi, N., Barazvan, B., & Soleimani Rad, J. (2016). Tumor microenvironment-mediated chemoresistance in breast cancer. Breast, 30, 92–100. Scholar
  88. Venditto, V. J., & Szoka, F. C. (2013). Cancer nanomedicines: So many papers and so few drugs! Advanced Drug Delivery Reviews, 65, 80–88. Scholar
  89. Venkatesan, M., & Jolad, B. (2010). Nanorobots in cancer treatment. In International conference on “Emerging trends in robotics and communication technologies”, INTERACT-2010 (pp 258–264).
  90. Weiner, George J. (2015). Building better monoclonal antibody-based therapeutics. Nature Reviews Cancer, 15, 361–370. Scholar
  91. Werner, M. E., Cummings, N. D., Sethi, M., et al. (2013). Preclinical evaluation of Genexol-PM, a nanoparticle formulation of paclitaxel, as a novel radiosensitizer for the treatment of non-small cell lung cancer. International Journal of Radiation Oncology* Biology* Physics, 86, 463–468. Scholar
  92. Wirth, T., & Ylä-Herttuala, S. (2014). Gene therapy used in cancer treatment. Biomedicines, 2, 149–162. Scholar
  93. Xu, X., Ho, W., Zhang, X., et al. (2015). Cancer nanomedicine: From targeted delivery to combination therapy. Trends in Molecular Medicine, 21, 223–232. Scholar
  94. Yang, C., Chan, K. K., Lin, W.-J., et al. (2017). Biodegradable nanocarriers for small interfering ribonucleic acid (siRNA) co-delivery strategy increase the chemosensitivity of pancreatic cancer cells to gemcitabine. Nano Research, 10, 3049–3067. Scholar
  95. Yang, L., Zhang, X., Ye, M., et al. (2011). Aptamer-conjugated nanomaterials and their applications. Advanced Drug Delivery Reviews, 63, 1361–1370. Scholar
  96. Zhang, H. (2016). Onivyde for the therapy of multiple solid tumors. OncoTargets and therapy, 9, 3001–3007. Scholar
  97. Zhang, J., Jiang, C., Figueiró Longo, J. P., et al. (2018). An updated overview on the development of new photosensitizers for anticancer photodynamic therapy. Acta Pharmaceutica Sinica B, 8, 137–146. Scholar
  98. Zhang, P., Hu, L., Yin, Q., et al. (2012). Transferrin-modified c[RGDfK]-paclitaxel loaded hybrid micelle for sequential blood-brain barrier penetration and glioma targeting therapy. Molecular Pharmaceutics, 9, 1590–1598. Scholar
  99. Zhang, Y., Yu, J., Zhang, L., et al. (2016). Enhanced anti-tumor effects of doxorubicin on glioma by entrapping in polybutylcyanoacrylate nanoparticles. Tumor Biology, 37, 2703–2708. Scholar
  100. Zou, L., Wang, H., He, B., et al. (2016). Current approaches of photothermal therapy in treating cancer metastasis with nanotherapeutics. Theranostics, 6, 762–772. Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  • Enas Abu-Qudais
    • 1
  • Balakumar Chandrasekaran
    • 1
    Email author
  • Sara Samarneh
    • 1
  • Ghadir Kassab
    • 1
  1. 1.Faculty of PharmacyPhiladelphia UniversityAmmanJordan

Personalised recommendations